Nina Martinez

Nina Martinez

Auto-generated profile, based on publicly available information

Nina Martinez

Department of Neurological Surgery, Thomas Jefferson University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2015 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
APA.J. Prager
A.J. Prager
NMN. Martinez
N. Martinez
KBK. Beal
K. Beal
AOA. Omuro
A. Omuro
ZZZ. Zhang
Z. Zhang
RYR.J. Young
R.J. Young
BACKGROUND AND PURPOSE: Treatment-related changes and recurrent tumors often have overlapping features on conventional MR imaging. The purpose of this study was to assess the utility of DWI and DSC perfusion imaging alone and in combination to differentiate treatment-related effects and recurrent high-grade gliomas. MATERIALS AND METHODS: We retrospectively identified 68 consecutive patients with high-grade gliomas treated by surgical resection followed by radiation therapy and temozolomide, who then developed increasing enhancing mass lesions indeterminate for treatment-related changes versus recurrent tumor. All lesions were diagnosed by histopathology at repeat surgical resection. ROI analysis was performed of the enhancing lesion on the ADC and DSC maps. Measurements made by a 2D ROI of the enhancing lesion on a single slice were recorded as ADCLesion and rCBVLesion, and measurements made by the most abnormal small fixed diameter ROI as ADCROI and rCBVROI. Statistical analysis was performed with Wilcoxon rank sum tests with P = .05. RESULTS: Ten of the 68 patients (14.7%) had treatment-related changes, while 58 patients (85.3%) had recurrent tumor only (n = 19) or recurrent tumor mixed with treatment effect (n = 39). DWI analysis showed higher ADCLesion in treatment-related changes than in recurrent tumor (P = .003). DSC analysis revealed lower relative cerebral blood volume (rCBV)Lesion and rCBVROI in treatment-related changes (P = .003 and P = .011, respectively). Subanalysis of patients with suspected pseudoprogression also revealed higher ADCLesion (P = .001) and lower rCBVLesion (P = .028) and rCBVROI (P = .032) in treatment-related changes. Applying a combined ADCLesion and rCBVLesion model did not outperform either the ADC or rCBV metric alone. CONCLUSIONS: Treatment-related changes showed higher diffusion and lower perfusion than recurrent tumor. Similar correlations were found for patients with suspected pseudoprogression.

23 March 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ASAndrew Song
Andrew Song
VBVoichita Bar-Ad
Voichita Bar-Ad
NMNina Martinez
Nina Martinez
JGJon Glass
Jon Glass
DADavid W. Andrews
David W. Andrews
WSWenyin Shi
Wenyin Shi

2 May 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ATAlissa A Thomas
Alissa A Thomas
LALauren E Abrey
Lauren E Abrey
RTRobert Terziev
Robert Terziev
JRJeffrey Raizer
Jeffrey Raizer
NMNina L Martinez
Nina L Martinez
AOAntonio Omuro
Antonio Omuro
Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day × 3 days, then busulfan 3.2 mg/kg/day × 3 days), followed by ASCT. Genomic characterization was performed using next-generation sequencing. Forty-one patients were enrolled; 85% had 1p/19q codeleted tumors. After induction, 26 patients were eligible for HDC-ASCT and 21 agreed to proceed. There were no unexpected adverse events or toxic deaths. After median follow-up of 66 months, 2-year progression-free survival (PFS) for transplanted patients was 86%, 5-year PFS 60%, and no patient has died. Among all 1p/19q codeleted patients (N = 33), 5-year PFS was 50% and 5-year overall survival (OS) 93%, with median time to radiotherapy not reached. Next-generation sequencing disclosed typical oligodendroglioma-related mutations, including IDH1, TERT, CIC, and FUBP1 mutations in 1p/19q codeleted patients, and glioblastoma-like signatures in 1p/19q intact patients. Aside from IDH1, potentially oncogenic/actionable mutations were variable, depicting wide molecular heterogeneity within oligodendroglial tumors. TMZ followed by HDC-ASCT can be safely administered to patients with newly diagnosed 1p/19q codeleted AO. This strategy was associated with promising PFS and OS, suggesting that a chemotherapy-based approach may delay the need for radiotherapy and radiation-related toxicities. Raw data for further genomic and meta-analyses are publicly available at http://cbioportal.org/study?id=odg_msk_2017, accessed 6 January 2017. NCT00588523

1 December 2011 in Journal of Dance Medicine & Science
Verified
Journal Article
Open access
NMNina Martinez
Nina Martinez
SMSteven Mandel
Steven Mandel
JPJudith R. Peterson
Judith R. Peterson
Hip pain in dancers is typically attributed to musculoskeletal etiologies due to local “wear-and-tear”; however, one must be aware of neurologic etiologies that may present with additional clinical findings and require specialized treatment. This article explores the presentation, potential causes, suggested work-up, and treatment options for femoral neuropathy, lateral femoral cutaneous syndrome, and piriformis syndrome.

1 January 2022
Verified
Conference Paper
Open access
PDF file
WSWenyin Shi
Wenyin Shi
Ryan S MillerRyan S Miller
Ryan S Miller
ASAndrew Song
Andrew Song
AAAyesha Ali
Ayesha Ali
VBVoichita Bar-Ad
Voichita Bar-Ad
HLHaisong Liu
Haisong Liu
Shi W, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S86. https://doi.org/10.14791/btrt.2022.10.F-1378

1 January 2022
Verified
Conference Paper
Open access
PDF file
WSWenyin Shi
Wenyin Shi
AAAyesha Ali
Ayesha Ali
MNMuneeb Niazi
Muneeb Niazi
VBVoichita Bar-Ad
Voichita Bar-Ad
MWMaria Werner-Wasik
Maria Werner-Wasik
KJKevin Judy
Kevin Judy
Shi W, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S179. https://doi.org/10.14791/btrt.2022.10.F-1386